HIV AIDS

Get a quick overview of recommendations for preventive health services and screenings focused on the unique needs of women across the lifespan.

Your daily dose of the clinical news you may have missed.

IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.

IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.

Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.

IDWeek 2023: Leading physician scientists will headline plenary sessions and named lectureships on topics ranging from antibiotic stewardship to artificial intelligence.

The USPSTF particularly emphasizes effective communication with patients, including adherence support and calls for reducing barriers to PrEP for racial, ethnic, and other minority groups.

Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.

Lenacapavir is the first of a new class of antiretrovirals, and it is indicated for persons with multidrug resistance, intolerance, or safety considerations.

New data showed a sharp drop in HIV tests administered in health care and non-health care settings from 2019 to 2020—primarily among persons disproportionately affected by HIV.